Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Names Clerie VP of Quality Assurance, Harkness Takes the Helm at Cell Biosciences, JCVI Announces Promotions, and More

NEW YORK (GenomeWeb News) - Illumina has named Fredrick Clerie to be VP of quality assurance and regulatory affairs. Clerie previously was VP of global quality assurance and regulatory affairs for Bayer Healthcare and he spent nearly a decade in multiple positions at Bayer Diagnostics.

Thermo Fisher Scientific has elected William Parrett to its board of directors. He also has been appointed to the firm’s audit committee. Parrett retired last year from his post as CEO of Deloitte Touche Tohmatsu.
He also is a member of the Committee on Capital Markets Regulation, the American Institute of Certified Public Accountants and the executive board for the International Chamber of Commerce. In addition, Parrett serves as chairman of the United States Council for International Business as well as the United Way of America.

Fluorotechnics has appointed David Weber to be a non executive director. Weber has served as president of GE Healthcare Bio-Sciences, CEO and president of Eksigent Technologies, and VP of global marketing and business development at Stratagene.

Tecan has named Domingo Messerli to be head of the company’s sample management business and a member of its executive board. Messerli was CEO of Elektrizitäts for three years and he held various management positions at the pharmaceutical, food, and chemical company Glatt.

Serigene has appointed Robert Bohrer to its board of directors. Borhrer was director of biotechnology programs at the University of California at San Diego’s Center for Molecular Medicine, and he currently is executive editor of Biotechnology Law Report.

Signature Genomic Laboratories has named Evan Jones, the principal of jVen Capital, which recently invested in the company, to serve on its board of directors.
Jones was co-founder and chairman of the board of directors of Digene, which was acquired last year by Qiagen. He is now chairman of the board of directors for the Children’s Research Institute at the Children’s National Medical Center. He also is chairman of the Campaign for Public Health, and a member of the board of directors and executive committee at Research!America.

Alexander Tropsha has joined Upstream Biosciences’ scientific advisory board. Tropsha is a scientist at the University of North Carolina at Chapel Hill and chair of the Division of Medicine Chemistry and Natural Products at the UNC Eshelman School of Pharmacy. He also is director of the Laboratory for Molecular Modeling at the School of Pharmacy and director of the UNC Graduate Program in Bioinformatics and Computational Biology.

Cell Biosciences has named Tim Harkness president and CEO, Richard Lussier VP of sales and international operations, and Walter Ausserer VP of marketing.
Harkness was CFO at Molecular Devices Corporation. Lussier formerly was involved in sales at Applied Biosystems, Celera Genomics, and Solexa. Ausserer formerly was involved in product development at Axela Biosensors, Caliper Life Sciences, and Dionex.

Battelle has named Kevin Xie to be VP of the company’s biomarker services division. Xie was director and head of global business development of specialty pharmaceuticals at Boehringer Ingelheim for the past two years, and before that he was director and head of global business development for diabetes care for Bayer Healthcare.

The J. Craig Venter Institute has named four staff promotions and advancements, including the promotion of Robert Friedman to deputy director of JCVI La Jolla, and three other promotions at the JCVI headquarters in Maryland.
Friedman formerly was VP of public policy, a role in which he focused on synthetic genomics and environmental genomics policies.
Karen Nelson has been appointed director of human microbiology and metagenomics in JCVI’s Human Genomic Medicine Group. Nelson currently is a principal investigator on a multi-center grant from the National Institutes of Health’s Human Microbiome Project.
Samuel Levy has been promoted to be director of human genomics at JCVI. Levy previously worked at Celera Genomics and he has been involved in Drosophila and human genome research.
Yu-Hui Rogers has been appointed VP of core technology development and services at JCVI. Rogers has worked in JCVI sequencing projects and she previously was manager of sequencing research and development at Celera.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.